An Evaluation of the Australian National Serosurveillance Program

Authors

  • Andrew Jardine National Centre for Epidemiology and Population Health, Australian National University, Australian Capital Territory; National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, The Children’s Hospital at Westmead and the University of Sydney, New South Wales
  • Shelley L Deeks National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, The Children’s Hospital at Westmead and the University of Sydney, New South Wales
  • Mahomed S Patel National Centre for Epidemiology and Population Health, Australian National University, Australian Capital Territory
  • Robert I Menzies National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, The Children’s Hospital at Westmead and the University of Sydney, New South Wales
  • Gwendolyn L Gilbert Centre for Infectious Diseases and Microbiology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, New South Wales
  • Peter B McIntyre National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, The Children’s Hospital at Westmead and the University of Sydney, New South Wales

DOI:

https://doi.org/10.33321/cdi.2010.34.4

Keywords:

evaluation, serological surveillance, vaccine preventable diseases

Abstract

The Australian National Serosurveillance Program (ANSP) was established in 1997 to provide national estimates of population immunity to vaccine preventable diseases and inform immunisation policy in Australia. The 1st round tested opportunistically collected sera from pathology laboratories across Australia, a 2nd round was carried out in 2002, and a 3rd round of testing is currently ongoing using sera from 2007–08. This is the 1st systematic evaluation of the ANSP since its inception. Existing information and outputs from the ANSP were reviewed and used in conjunction with data collected from a survey of the program operators to evaluate the overall utility of the ANSP and the following system attributes; acceptability, stability, simplicity, flexibility, data quality, sensitivity, representativeness and timeliness. So far the ANSP has generated 26 peer-reviewed publications and provided useful data that have influenced and provided an evidence base for immunisation policy in Australia; for example informing mathematical models, which identified the need for the young adult measles-mumps-rubella immunisation campaign. However, difficulties have been encountered with obtaining enough samples for testing in the 3rd round currently being undertaken. This is a concern that has the potential to undermine the representativeness and stability of the system, and other methods of sample collection must be investigated. Serological surveillance is an important component of any comprehensive system for monitoring population immunity to vaccine preventable diseases and evaluating the effectiveness of immunisation programs. However, an effective ongoing program requires strong support to ensure it remains sustainable in an era when laboratory based population health research for the public good is becoming increasingly challenging. Commun Dis Intell 2010;34(1):28–35.

Downloads

Download data is not yet available.

References

Gidding H. Australia’s national serosurveillance program. NSW Public Health Bull 2003;14(4–5):90–93.

Osborne K, Gay N, Hesketh L, Morgan-Capner P, Miller E. Ten years of serological surveillance in England and Wales: methods, results, implications and action. Int J Epidemiol 2000;29(2):362–368.

Andrews N, Tischer A, Siedler A, Pebody RG, Barbara C, Cotter S, et al. Towards elimination: measles susceptibility in Australia and 17 European countries. Bull World Health Organ 2008;86(3):197–204.

De Melker HE, Conyn-van Spaendonck MA. Immunosurveillance and the evaluation of national immunization programmes: a population-based approach. Epidemiol Infect 1998;121(3):637–643.

Gergen PJ, McQuillan GM, Kiely M, Ezzati-Rice TM, Sutter RW, Virella G. A population-based serologic survey of immunity to tetanus in the United States. N Engl J Med 1995;332(12):761–766.

German RR, Lee LM, Horan JM, Milstein RL, Pertowski CA, Waller MN, et al. Updated guidelines for evaluating public health surveillance systems: recommendations from the guidelines working group. MMWR Recomm Rep 2001;50(RR-13):1–35.

Gilbert GL, Escott RG, Gidding HF, Turnbull FM, Heath TC, McIntyre PB, et al. Impact of the Australian Measles Control Campaign on immunity to measles and rubella. Epidemiol Infect 2001;127(2):297–303.

Turnbull FM, Burgess MA, McIntyre PB, Lambert SB, Gilbert GL, Gidding HF, et al. The Australian Measles Control Campaign, 1998. Bull World Health Organ 2001;79(9):882–888.

McIntyre PB, Gidding HF, Gilbert GL. Measles in an era of measles control. Med J Aust 2000;172(3):103–104.

Gidding HF, Young M, Pugh R, Burgess M. Rubella in Australia: can we explain two recent cases of congenital rubella syndrome? Commun Dis Intell 2003;27(4):537–540.

Backhouse JL, Gidding HF, McIntyre PB, Gilbert GL. Evaluation of two enzyme immunoassays for detection of immunoglobulin G antibodies to mumps virus. Clin Vaccine Immunol 2006;13(7):764–767.

Kelly H, Riddell MA, Gidding HF, Nolan T, Gilbert GL. A random cluster survey and a convenience sample give comparable estimates of immunity to vaccine preventable diseases in children of school age in Victoria, Australia. Vaccine 2002;20(25–26):3130–3136.

MacIntyre CR, Gay NJ, Gidding HF, Hull BP, Gilbert GL, McIntyre PB. A mathematical model to measure the impact of the Measles Control Campaign on the potential for measles transmission in Australia. Int J Infect Dis 2002;6(4):277–282.

Gidding HF, Brisson M, Macintyre CR, Burgess MA. Modelling the impact of vaccination on the epidemiology of varicella zoster virus in Australia. Aust N Z J Public Health 2005;29(6):544-551.

Gidding HF, Gilbert GL. Measles immunity in young Australian adults. Commun Dis Intell 2001;25(3):133–136.

Aratchige PE, McIntyre PB, Quinn HE, Gilbert GL. Recent increases in mumps incidence in Australia: the ‘forgotten’ age group in the 1998 Australian Measles Control Campaign. Med J Aust 2008;189(8):434–437.

Gidding HF, MacIntyre CR, Burgess MA, Gilbert GL. The seroepidemiology and transmission dynamics of varicella in Australia. Epidemiol Infect 2003;131(3):1085–1089.

Amin J, Gilbert GL, Escott RG, Heath TC, Burgess MA. Hepatitis A epidemiology in Australia: national seroprevalence and notifications. Med J Aust 2001;174(7):338–341.

O’Sullivan BG, Gidding HF, Law M, Kaldor JM, Gilbert GL, Dore GJ. Estimates of chronic hepatitis B virus infection in Australia, 2000. Aust N Z J Public Health 2004;28(3):212–216.

Wood N, Backhouse J, Gidding HF, Gilbert GL, Lum G, McIntyre PB. Estimates of chronic hepatitis B virus infection in the Northern Territory. Commun Dis Intell 2005;29(3):289–290.

Amin J, Gidding H, Gilbert G, Backhouse J, Kaldor J, Dore G, et al. Hepatitis C prevalence—a nationwide serosurvey. Commun Dis Intell 2004;28(4):517–521.

Gidding HF, Backhouse JL, Burgess MA, Gilbert GL. Immunity to diphtheria and tetanus in Australia: a national serosurvey. Med J Aust 2005;183(6):301–304.

Gidding HF, Backhouse JL, Gilbert GL, Burgess MA. National serosurvey of poliovirus immunity in Australia, 1996–99. Aust N Z J Public Health 2005;29(1):48–52.

Cagney M, MacIntyre CR, McIntyre P, Puech M, Giammanco A. The seroepidemiology of pertussis in Australia during an epidemic period. Epidemiol Infect 2006;134(6):1208–1216.

Gidding HF, Wood J, MacIntyre CR, Kelly H, Lambert SB, Gilbert GL, et al. Sustained measles elimination in Australia and priorities for long term maintenance. Vaccine 2007;25(18):3574–3580.

Kelly HA, Gidding HF, Karapanagiotidis T, Leydon JA, Riddell MA. Residual susceptibility to measles among young adults in Victoria, Australia following a national targeted measles-mumps-rubella vaccination campaign. BMC Public Health 2007;7:99.

Gilbert GL, Gidding HF, Backhouse J, McIntyre PB. Varicella seroprevalence and vaccine uptake in preschool children. Med J Aust 2005;182(1):42.

Gidding HF, Warlow M, MacIntyre CR, Backhouse J, Gilbert GL, Quinn HE, et al. The impact of a new universal infant and school-based adolescent hepatitis B vaccination program in Australia. Vaccine 2007;25:8637–8641.

Backhouse JL, Gidding HF, MacIntyre CR, McIntyre PB, Gilbert GL. Population-based seroprevalence of Neisseria meningitidis serogroup C capsular antibody before the introduction of conjugate vaccine, in Australia. Vaccine 2007;25(51):1310–1315.

Seale H, MacIntyre CR, Gidding HF, Backhouse JL, Dwyer DE, Gilbert L. National serosurvey of cytomegalovirus in Australia. Clin Vaccine Immunol 2006;13(11):1181–1184.

Moujaber T, Backhouse JL, Gidding HF, Quinn H, Gilbert GL, MacIntyre CR. The seroepidemiology of Helicobacter pylori infection in Australia. Int J Inf Dis 2008;12(5):500–504.

Campbell M. Young adult measles vaccination. Commun Dis Intell 2000;24(8):241–242.

Heywood AE, Gidding HF, Riddell MA, McIntyre PB, MacIntyre CR, Kelly HA. Elimination of endemic measles transmission in Australia. Bull World Health Organ 2009;87(1):64–71.

Burnett JJ. Psychographic and demographic characteristics of blood donors. J Consum Res 1981;8:62–66.

Ford I. Is blood donation good for the donor? Heart 1997;78(2):107.

Gordis L. Epidemiology. Philidelphia, PA, USA: W. B. Saunders Company; 1996.

Downloads

Published

31/03/10

How to Cite

Jardine, Andrew, Shelley L Deeks, Mahomed S Patel, Robert I Menzies, Gwendolyn L Gilbert, and Peter B McIntyre. 2010. “An Evaluation of the Australian National Serosurveillance Program”. Communicable Diseases Intelligence 34 (March):29-36. https://doi.org/10.33321/cdi.2010.34.4.

Issue

Vol. 34 (2010)

Section

Original article

Categories

License

Copyright (c) 2010 Communicable Diseases Intelligence

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Most read articles by the same author(s)

1 2 3 4 5 6 > >>